CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to develop an innovative endobronchial stent, called PulmoStent, for treating lung cancer. This stent combines advanced stent technologies with tissue engineering to maintain airway function and deliver localized cancer therapies, addressing significant challenges in current treatment methods.
Lung cancer is the most common cancer in terms of both incidence and mortality, worldwide.
With a median age at diagnosis of 71, lung cancer is mainly affecting the aging population.
Airway stenosis is a key problem with significant morbidity and premature death.
Endobronchial stenting is a proven therapy to keep the airways open.
Nevertheless the currently used clinical stents have major disadvantages either by rapid re-occlusion due to tumour ingrowths (metal stents) or massive mucus retention…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Ireland, Galway
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Aachen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Utrecht
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, Plan Les Ouates
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
